TAO Synergies is a clinical-stage biopharmaceutical company that develops novel therapies for neurodegenerative diseases.
TAO Synergies has raised $11.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2025.
TAO Synergies's investors include Bantam Group.
TAO Synergies is headquartered in New York, United States.
TAO Synergies is a clinical-stage biopharmaceutical company that develops novel therapies for neurodegenerative diseases.
TAO Synergies is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"TAO Synergies — Funding & Investors." VCBacked, October 13, 2025, https://www.vcbacked.co/company/tao-synergies. Accessed August 14, 2026.
VCBacked. (2025). TAO Synergies — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/tao-synergies
{{cite web |title=TAO Synergies — Funding & Investors |url=https://www.vcbacked.co/company/tao-synergies |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated